Thromboseprophylaxe und Antikoagulation in der Intensivmedizin

Koagulopathien sind potenziell lebensbedrohlich, doch auch eine erhöhte Thromboseneigung stellt ein erhebliches Risiko dar. Ein hohes Thrombembolierisiko bei Intensivpatienten erfordert in der Regel eine prophylaktische, teilweise therapeutische Antikoagulation. In einer observationellen Studie erfolgte bei ca. 50% aller Patienten die Thromboseprophylaxe nicht adäquat [1].

Schlüsselwörter

Gerinnung - Thrombose - Antikoagulation - HIT - Heparin-induzierte Thrombozytopenie

• Literatur

• 1 Cohen AT, Tapson VF, Bergmann JF. et al. Venous thrombembolism risk and prophylaxis in the acute hospital care setting (ENDORSE study): a multimodal cross-sectional study. Lancet 2008; 371: 387-394
• 2 Pfanner G, Koscielny J, Pernerstorfer T. et al. Präoperative Blutungsanamnese. Anästhesist 2007; 56: 604-611
• 3 Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften e. V. (AWMF). S3 Leitlinie Prophylaxe der venösen Thrombembolie (VTE). Leitlinien-Register Nr. 003/0012. Aufl. Stand: 15.10.2015. Im Internet (Stand: 12.09.2021) https://www.awmf.org/uploads/tx_szleitlinien/003–001l_S3_VTE-Prophylaxe_2015–10-abgelaufen_01.pdf
• 4 The PROTECT Investigators for the Canadian Critical Care Trials Group and the Australian and New Zealand Intensiv Care Society Clinical Trials Group. Deltaparin versus unfractionated heparin in critical ill patients. N Engl J Med 2011; 364: 1305-1314
• 5 Kearon C, Akl EA, Ornelas J. et al. Antithrombotic therapie for VTE disease. CHEST Guideline and Expert Panel Report. Chest 2016; 149: 315-352
• 6 Sibley S, Muscedere J. New-onset atrial fibrillation in critically ill patients. Can Respir J 2015; 22: 179-182
• 7 Arrigo M, Bettex D, Rudiger A. Behandlung von Vorhofflimmern in der Intensiv-und Notfallmedizin. Med Klin Intensivmed Notfmed 2015; 110: 614-620
• 8 Walkey AJ, Quinn EK, Winter MR. et al. Practice patterns and outcomes associated with use of anticoagulation among patients with atrial fibrillation during sepsis. JAMA Cardiol 2016; 1: 682-690
• 9 Hindricks G, Potpara T, Dagres N. et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the Eurpopean Association of Cardio-Thoracic Surcery (EACTS). Eur Heart J 2020; 42: 373-498
• 10 Salem DN, O’Gara PT, Madias C. et al. Valvular and structural heart disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th ed.). Chest 2008; 133: 593-629
• 11 Salem DN, Stein PD, Al-Ahmad A. et al. Antithrombotic therapy in valvular heart disease – native and prosthetic: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126: 457-482
• 12 Douketis JD, Spyropoulos AC, Kaatz S. et al. Perioperative bridging anticoagulation in patients with atrial fibrillation. N Engl J Med 2015; 373: 823-833
• 13 Steinberg BA, Peterson ED, Kim S. et al. Use and outcomes associated with bridging during anticoagulation interruptions in patients with atrial fibrillation. Circulation 2015; 131: 488-494
• 14 Siegal D, Yudin J, Kaatz S. et al. Periprocedural heparin bridging in patients receiving vitamin k antagonists, systematic review and meta-analysis of bleeding and thromboembolic rates. Circulation 2012; 126: 1630-1639
• 15 Rechenmacher S, Fang JC. Bridging Anticoagulation, Primum Non Nocere. JACC 2015; 66: 1392-1403
• 16 Baron TH, Kamath PS, McBane RD. Management of antithrombotic therapy in patients undergoing invasive proceduresN Engl. J Med 2013; 368: 2113-2124
• 17 Douketis JD, Spyropoulos AC, Spencer FA. et al. Perioperativ management of antithrombotic therapy: antithrombotic therapie and prevention of throbosis, 9th edn. American College of Chest Physicians Evidance-Based Clinical Practice Guidelines. Chest 2012; 141: 326-350
• 18 Bayer-Westendorf J, Gelbricht V, Förster K. et al. Peri-interventional management of novel oral anticoagulants in daily care: results from the prospective Dresden NOAC Registry. Europ Heart J 2014; 35: 1888-1896
• 19 Warkentin TE, Greinacher A. Management of heparin-induced thrombocytopenia. Curr Opin Hematol 2016; 23: 462-470
• 20 Warkentin TE. Heparin-induced thrombozytopenie in critical ill patients. Semin Thromb Hemost 2015; 41: 49-60
• 21 Beck GC, Dempfle CE. Wann ist ein HIT ein HIT?. Anästh Intensivmed 2008; 49: 456-467